Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 7/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CASP1 | P29466 | 3/20 | 0.32 |
| ▸ | CASP7 | P55210 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988460 | 0.93 | PDE3B (0.32) | PDE3BPDE3ACA2TNK2IGF1R | |
| SCHEMBL2987877 | 0.90 | PDE3B (0.31) | PDE3BPDE3A | |
| SCHEMBL2985014 | 0.89 | PLK1 (0.33) | IGF1RPLK1ALDH1A1 | |
| SCHEMBL2971724 | 0.89 | PDE3B (0.35) | PDE3BPDE3ACLK1CLK2TNK2 | |
| SCHEMBL2974581 | 0.88 | — | — | |
| SCHEMBL2986248 | 0.88 | ABL1 (0.31) | — | |
| SCHEMBL2983650 | 0.88 | SRC (0.34) | TNK2IGF1RKDRCYP1A2 | |
| SCHEMBL2984529 | 0.88 | ADRB3 (0.30) | — | |
| SCHEMBL2973307 | 0.88 | PDE3B (0.41) | PDE3BPDE3AHDAC6TSHR | |
| SCHEMBL2980471 | 0.88 | PDE3B (0.40) | PDE3BPDE3AHDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | PDE3B 3421/4885PDE3A 3635/4885CLK1 363/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | PDE3B 3421/4885PDE3A 3635/4885CLK1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.